Microsoft on Monday unveiled “Copilot Mode,” an AI-powered tool for its Microsoft Edge browser.
Copilot Mode, currently available for free, can view a user’s open tabs and execute tasks on their behalf.
Copilot Mode launches on the heels of Google’s AI Mode for Chrome, which debuted earlier this year.
Microsoft is due to report quarterly earnings after the closing bell Wednesday.
Microsoft (MSFT) rolled out an AI assistant for its Edge browser Monday, as the tech giant works to compete with Alphabet’s (GOOGL) Google and others offering AI search tools.
Microsoft’s “Copilot Mode” displays a “clean, streamlined page with a single input box that brings together chat, search and web navigation,” Microsoft said in a blog post. Users can type commands into the input box, or use voice commands directly to prompt tasks like comparing travel listings pulled up across multiple tabs. Copilot Mode is currently available for free, but only for a limited time, the blog post said.
Microsoft said users will eventually be able to give Copilot Mode access to their browser history and credentials in order to complete more complex tasks. For example, a demonstration video showed a user prompting Copilot Mode to find a paddleboard rental place near their workplace—the AI assistant pulled one up, identified a day with good weather, and offered to make a booking.
AI integration has become a key area of focus for America’s search giants as the use of generative AI chatbots like OpenAI’s ChatGPT becomes more widespread, threatening traditional search traffic. In May, Google launched AI Mode, which lets users ask questions in conversation with Gemini. AI Mode has already reached 100 million monthly active users in the U.S. and India, CEO Sundar Pichai said on Alphabet’s earnings call last week.
Analysts will get a chance to ask Microsoft CEO Satya Nadella about Copilot Mode when the company reports earnings after the closing bell Wednesday. Shares of Microsoft were little changed Monday, but have surged more than 20% in 2025.
Maybe if you lost some weight, someone would actually like you.
No filter can fix that face.
These are the sorts of comments teenage girls see online daily, via social media, group chats, or anonymous messages. While some may dismiss this as teasing, these comments constitute appearance-related cyberbullying.
Our previous research shows appearance-related cyberbullying is one of the most common and harmful forms of online abuse of young people. It not only hurts feelings – it changes how teens, particularly girls, see themselves.
In a new study, we’ve looked at brain images of teenage girls viewing appearance-related cyberbullying. We’ve found even just being exposed to online body shaming directed at others can activate regions of the brain linked to emotional pain and social threat.
What is appearance-related cyberbullying?
Appearance-related cyberbullying is any online behaviour that targets the way someone looks. This includes comments about their face, clothes or body. It often happens in public forums, such as comment sections or social media posts, where other people can see it, join in or share it.
The most damaging type focuses on someone’s body, such as their weight, shape or size. These messages don’t need to be long or explicit to hurt. Sometimes a single word, hashtag or even emoji is enough.
While appearance-related bullying can affect anyone, previous studies have shown teenage girls are particularly vulnerable.
During adolescence, the brain is still developing – especially the parts that shape self-esteem and help us make sense of how others see us. This means teenagers can be more affected by what people say about them.
What’s more, girls often feel strong societal pressure to look a certain way. This combination makes body shaming especially harmful.
How common is it?
In a survey of 336 teenage girls we published last year, 98% had experienced some form of cyberbullying. For 62% of them, the abuse targeted their appearance.
Most of those girls said this bullying had lasting effects on their body image and mental health, with 96% saying it made them want to change how they looked. More than 80% felt they needed to consider cosmetic procedures.
Studies from around the world have shown appearance-related cyberbullying is a strong predictor of body dissatisfaction, which is one of the biggest risk factors for eating disorders in teenage girls.
What does it do to the brain?
To understand how body-shaming content affects girls on a deeper level, we designed a brain imaging study.
First, we created a set of social media posts based on typical comments teenage girls see online. Some posts were neutral, while others included body shaming comments.
We created social media posts like this one for our study. Author provided
More than 400 girls rated how realistic and emotionally powerful these posts were. This helped us validate the content so it could be used in current and future studies on how young people respond to body shaming online.
We then invited 26 girls aged 14 to 18, from the Longitudinal Adolescent Brain Study – a five-year research project at our university seeking to better understand how the teenage brain develops and how this relates to mental health – to take part in a brain scan study.
We used functional MRI, a technique that shows which areas of the brain are more active during certain experiences. Alongside the scans, participants completed questionnaires about their recent experiences of cyberbullying and their body image.
When girls viewed body-shaming posts, we found certain brain regions “lit up” more than others. These included areas involved in emotional pain, self-image, and social judgement. These are regions the brain uses to interpret how others see us, and how we deal with feelings such as shame or rejection.
Girls who had recently been cyberbullied showed more activity in memory and attention regions. This suggests they were reprocessing earlier, painful experiences. Girls with more positive body image, meanwhile, showed calmer, more regulated brain responses, suggesting healthy self-image might be protective.
Appearance-related cyberbullying can have lasting effects on body image. Samuel Borges Photography/Shutterstock
Girls are affected even when they’re not targeted
Notably, the girls in our study were viewing posts aimed at others – not being subjected to bullying directly. But even so, we saw changes in the way their brains reacted, and how they felt about their own bodies seemed to affect these reactions.
This tells us something important: body-shaming content doesn’t just hurt the person it targets. When appearance is constantly judged and criticised, it can change what girls think is normal or acceptable. It may also affect how their brains respond to social and emotional situations.
What needs to change?
Appearance-related cyberbullying is not just about teenage conflict. It’s a wider, societal issue. Social media platforms reward content that grabs attention, even when it causes harm.
All of this is happening during a sensitive period of brain development, where social feedback shapes how teenagers see themselves and others.
To reduce harm, we need to act on multiple levels:
start early: while some schools offer lessons on body image and online safety, these topics are not taught consistently. Many young people say they want more support in dealing with appearance-related pressure online
support parents and educators: adults need tools, resources and language to talk with young people about what they see online, without shame or blame
hold platforms accountable: social media companies should strengthen reporting systems, and better moderate content that may promote appearance-related abuse such as “before-and-after” posts or other viral trends that target how someone looks
celebrate all body types: schools, media and influencers can help by showing real people with different body types and focusing on strengths such as kindness, talent, or what bodies can do.
Adolescence is a time of major change in how teenagers think, manage emotions and build relationships. What teenagers experience during these years can shape how they see themselves and understand the world.
Online body shaming may seem like just words on a screen. But if we want the next generation to grow up confident and well, we need to take it seriously.
In Australia, if you are experiencing body image concerns, you can contact the Butterfly Foundation’s national helpline on 1800 33 4673 (or use their online chat).
Ciara is gearing up for the release of her CiCi album, slated for an Aug. 22 arrival. In celebration of the second annual Ciara Day in Atlanta, the Grammy-winning singer returned on Monday (July 28) with “This Right Here,” which finds her tag-teaming with Latto for the first time.
Explore
See latest videos, charts and news
See latest videos, charts and news
The bouncy production packs on the nostalgia as Cici reunites with Jazze Pha behind the boards, which has been a dynamic combination in the past, as they’ve previously joined forces for catalog-defining smashes “1, 2 Step” and “Goodies.”
“‘This Right Here’ is the type of collaboration I always dreamt of! Being together with my hometown friends on this record means so much to me,” Ciara said in a statement. “Also knowing the amazing history that Jazze Pha and I have had together makes this moment, extra special. I want to thank Latto for bringing her infectious ATL girl energy to this record.”
Latto takes the baton and has fun with the pop-rap tune while saluting bars from Drake’s “In My Feelings.”
“A b—h from the South love a mouth full of gold/ No Chanel, I’m with CC/ Throw it back on ’em like Freaknik/ Do you love me like Kiki,” she raps.
Ciara called the bubbly collab one of her “favorite tracks on the album and I’m so excited that my fans will get to hear this record.”
CiCi hits streaming services on Aug. 22 and will be released independently on Ciara’s Beauty Marks Entertainment label. The 14-track album boasts features from Chris Brown, Lil Baby, Big Freedia, Busta Rhymes and Bossman Dlow.
Adam Lambert (Photo by Emilio Madrid for Broadway.com)
Here’s a quick roundup of stories you might have missed.
Adam Lambert to Release New Recording of “Heaven on Their Minds” from Jesus Christ Superstar
On August 1, opening night of Jesus Christ Superstar at the Hollywood Bowl, Adam Lambert (the production’s Judas) and composer Andrew Lloyd Webber will release a new studio recording of the show’s opening number, “Heaven on Their Minds.” As previously announced, the Hollywood Bowl production will star Cynthia Erivo as Jesus, with Tony nominee Phillipa Soo as Mary, Tony nominee Josh Gad as Herod, Tony nominee Raúl Esparza as Pontius Pilate and Milo Manheim as Peter. Performances run from August 1-3.
The Gilded Age Will Return for Season Four on HBO
HBO’s period drama The Gilded Age, featuring a cast of stage icons, has been renewed for a fourth season. Set in 1880s New York City, the Julian Fellowes series follows the new-money-versus-old-money tensions and upstairs-downstairs dramas of Manhattan society. The company of theater veterans includes Carrie Coon, Morgan Spector, Cynthia Nixon, Christine Baranski, Audra McDonald, Kelli O’Hara, Denée Benton, Louisa Jacobson, among many others. The show’s third season finale is scheduled to air August 10.
The Producers Completes West End Casting
The West End transfer of Mel Brooks and Thomas Meehan’s The Producers, directed by Patrick Marber, has its full cast. Joining the previously announced Andy Nyman as Max Bialystock, Marc Antolin as Leo Bloom, Trevor Ashley as Roger DeBris, Raj Ghatak as Carmen Ghia, Harry Morrison as Franz Liebkind and Joanna Woodward as Ulla, are Alex Lodge (Storm Trooper), Kelsie-Rae Marshall (Hold-Me-Touch-Me), Megan Armstrong, Olly Christopher, Gabrielle Cocca (Dance Captain), Nolan Edwards, Michael Franks, Matt Gillett (Resident Director), Esme Kennedy, Sinead Kenny, Josh Kiernan (Assistant Dance Captain), Kate Parr, Emma Robotham-Hunt, Pierce Rogan, Hollie Jane Stephens, Jermaine Woods and Ryan Pidgen. Performances will run at the Garrick Theatre from August 30 through February 21, 2026.
Elaine Paige and Bernadette Peters to Co-Host Third Annual Live West End Woofs (and Meows) Adoption Event
Dame Elaine Paige and Bernadette Peters will return to co-host West End Woofs (and Meows), their third annual live event at St Paul’s Church, Covent Garden, on August 9. Bringing together much-loved talent of the West End and their four-legged friends, West End Woofs (and Meows) is a live dog and cat adoption event, working with participating shelters and rescue groups to benefit their charitable work. Paige and Peters first teamed up to co-host the virtual edition of West End Woofs during lockdown in 2020 before hosting their first live event in 2023. The New York iteration, Broadway Barks, launched in 1999.
Dylan Mulvaney’s The Least Problematic Woman in the World Sets Off-Broadway Premiere
Dylan Mulvaney will bring her one-woman show, The Least Problematic Woman in the World, to the off-Broadway stage at the Lucille Lortel Theatre this fall. Written by and starring Mulvaney with direction by Tim Jackson, the autobiographical play follows Mulvaney’s journey from Catholic school kid to trans TikTok icon. Performances run from September 20 through November 30 with an official October 7 opening. The show previously enjoyed a sold-out run at the Edinburgh Fringe Festival.
Leishmaniasis, a neglected tropical disease caused by Leishmania parasites, affects millions globally. Current synthetic treatments face limitations including toxicity, cost, and resistance. Phytochemicals from medicinal plants offer promising alternatives. This mini-review synthesizes preclinical mechanisms of plant-derived compounds against leishmaniasis, focusing on mitochondrial disruption, immunomodulation, and redox imbalance.
No clinical trials: Limited human pharmacokinetic/pharmacodynamic data.
Combination potential: Synergy with existing drugs (e.g., amphotericin B) underexplored.
Standardization: Bioactive variability in plant extracts complicates dosing.
Future perspectives
Mechanistic depth: Validate mitochondrial targeting and immunomodulatory pathways.
Clinical studies: Prioritize phase I trials for lead compounds (e.g., artemisinin derivatives).
Drug delivery: Optimize bioavailability of hydrophobic terpenoids.
Natural libraries: Screen unexplored plant species for novel scaffolds.
Conclusion
Since the beginning of time, dietary, medicinal, and aromatic plants, as well as their active constituents, have been used to treat a wide range of human ailments worldwide, including leishmaniasis. This practice served as the foundation for modern or contemporary medicine. Several natural compounds obtained from medicinal plants (phytochemicals) have shown strong effects against different Leishmania species in preclinical studies under both in vitro and in vivo conditions. Medicinal plant-derived compounds can effectively manage leishmaniasis by killing the parasite and preventing its growth and transmission to hosts. The mechanisms, as extracted from the scientific literature, include disruption of cytoplasmic and mitochondrial membranes, induction of apoptosis and autophagy, gene expression and immunomodulatory pathways, pro-oxidant effects (disrupting cellular redox equilibrium) with mitochondrial dysfunction, cell cycle arrest, impaired cellular bioenergetics (ATP production), protein/enzyme interaction, and coagulation of cellular contents within the Leishmania parasites. The mitochondrion of the parasite (Leishmania has only one mitochondrion) is the chief target of most of the active natural products.
Source:
Journal reference:
Bhattacharya, S. (2025). Unravelling Antileishmanial Mechanisms of Phytochemicals: From Mitochondrial Disruption to Immunomodulation. Future Integrative Medicine. doi.org/10.14218/fim.2025.00021.
On July 18, NASA successfully launched a sounding rocket mission from the White Sands Missile Range in New Mexico, carrying a remarkable new technology. Its goal is to capture high-speed, high-resolution, multidimensional data from one of the Sun’s least understood regions, the chromosphere and transition region.
The chromosphere is a layer of the Sun’s atmosphere between its visible surface and the corona, or outer atmosphere. This region is where solar flares, jets and coronal mass ejections develop. Temperatures in this region rise rapidly, ranging from ~6000°C in the photosphere to over a million degrees in the corona. The instrument, the Solar EruptioN Integral Field Spectrograph (SNIFS), will provide researchers with insights about how this region of the Sun heats so quickly.
“SNIFS is a unique instrument where we implement novel integral field spectroscopy (IFS) technique for the first time to probe the sun’s chromosphere in UV from space,” Said SETI Institute research scientist and co-investigator of the SNIFS sounding rocket mission, Dr. Souvik Bose.
Understanding the Sun’s dynamic outer atmosphere is important because space weather and solar storms can impact communications on Earth, potentially causing GPS blackouts, satellite damage, and affecting the safety of astronauts.
SNIFS is a first-of-its-kind instrument in solar science. It’s an ultraviolet integral field spectrograph (IFS), and this mission marks the first time scientists have used this powerful IFS technology in a heliophysics space mission. Unlike instruments that scan a scene one slit position at a time, SNIFS will observe the chromosphere using rarely explored spectral lines, such as hydrogen Lyman-alpha and Si III/O V, allowing the team to trace plasma flows, heating, and energy release in real-time. It captures full spectral data across a 2D field of view at 1-second cadence — no scanning.
NASA’s sounding rocket missions are small, quick, and less expensive missions with smaller payloads. Teams design them to test new technologies and instruments and determine whether to scale up the technology for larger, multi-year missions in the future. SNIFS observed the Sun for just 10 minutes during its flight, but the data it collected could offer critical insights into the nature of heating of the outer atmosphere of the Sun.
SNIFS targeted a complex active region (AR4143) located slightly to the North-West of the Sun’s disk center, along with NASA’s IRIS and JAXA’s Hinode satellite. While no flares erupted during the flight, targeting this active region ensured that a detailed study could be performed to investigate the heating and mass flows in the solar atmosphere.
The rocket was retrieved immediately upon its return to Earth (landed 50 miles away from the launch site), allowing the team to begin processing the data, which is expected to take a few months.
Despite SNIFS’ short, suborbital flight, the science and technology it’s demonstrating could shape the next generation of solar observatories — and set a precedent for rapid, high-fidelity diagnostics of eruptive events.
As the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) continues to evolve, novel agents that offer both efficacy and convenience are gaining traction. One such investigational therapy is golcadomide (GOLCA, Bristol Myers Squibb), a first-in-class, oral cereblon E3 ligase modulator (CELMoD) that has demonstrated promising clinical activity in combination with rituximab (GOLCA-R, Rituxan; Genentech). Updated results from the phase 1/2 CC-99282-NHL-001 study (NCT03930953), presented at the European Hematology Association (EHA) 2025 Congress, revealed an objective response rate (ORR) of 58% and complete response rate (CRR) of 44% at the 0.4 mg dose level, with responses observed across molecular subtypes and high-risk groups—including patients previously treated with CAR T-cell and bispecific antibody therapies.
Despite its encouraging efficacy profile, the regimen is associated with notable hematologic toxicities, including grade 3/4 neutropenia in 64% of patients and febrile neutropenia in 10%, underscoring the need for proactive supportive care strategies. With GOLCA advancing into phase 3 development, including in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in the frontline setting (GOLSEEK-1 trial [NCT06356129]), the role of oncology pharmacists will be critical in managing cytopenias, optimizing prophylactic measures, and guiding outpatient implementation of this novel chemo-free regimen.
In this interview, Julio C. Chavez, MD, MS, associate member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center and co-investigator on the GOLCA study, discusses the clinical implications of the EHA 2025 data, dosing and safety considerations for pharmacists, and how GOLCA-R may help reshape DLBCL treatment pathways.
Pharmacy Times: As an oral, outpatient-administered therapy, how could GOLCA-R help shift DLBCL treatment paradigms away from hospital-based regimens, and what are the key challenges pharmacists should prepare for?
Julio C. Chavez, MD, MS, is an associate member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center and co-investigator on the GOLCA study.
Julio C. Chavez, MD, MS: I think the management of cytopenias will be key to manage for these patients. I would recommend considering preemptive granulocyte colony-stimulating factor (G-CSF) on patients who had more than 3 lines of therapy (specially post–CAR T-cell therapy and post–auto hematopoietic cell transplantation). Antibiotic prophylaxis should be considered for those at risk of infections such as elderly, neutropenia despite growth factors, and prior febrile neutropenia episodes. They should familiarize themselves with the dosing and schedule as well as dose reduction strategies. Also counseling with other potential adverse effects (AEs) that can be seen with immunomodulatory drugs, such as lenalidomide such as gastrointestinal AEs, rashes and neuropathy which is less frequent GOLCA, a CELMoD, per clinical studies.
Pharmacy Times: Given that responses appear independent of cell of origin and tumor microenvironment, do you foresee GOLCA-R being applicable across molecular DLBCL subtypes in future standard-of-care pathways?
Chavez: Responses independent of cell of origin was an interesting finding. We also saw responses in patients with high grade B-cell lymphomas, including those with MYC and BCL2 rearrangements.
Pharmacy Times: With an ORR of 58% and CRR of 44% at 0.4 mg, how do GOLCA-R outcomes compare to other chemo-free regimens for patients who previously received CAR T-cell or bispecific antibody therapies?
Chavez: Both epcoritamab (Epkinly; Genmab and AbbVie) and glofitamab (Columvi; Roche Pharmaceuticals) have similar response rates than GOLCA-R which is very encouraging given the logistics needed for bispecific antibodies. With CAR T-cell therapies (such as axicabtagene ciloleucel [Yescarta; Kite Pharma] and lisocabtagene maraleucel [Breyanzi; Bristol Myers Squibb), the ORR and CRR rates are higher and the follow up is longer. It is difficult to compare to a regimen such as lenalidomide (Revlimid; Bristol Myers Squibb) plus tafasitamab (Monjuvi; Incyte Corporation) as the L-MIND trial (NCT02399085) was very selective for patients with R/R DLBCL. However, when compared with real world data of lenalidomide plus tafasitamab, the efficacy of GOLCA-R seems superior.
Pharmacy Times: What clinical or molecular characteristics—such as TP53 or BCL2 mutations—have shown potential as predictive markers of response, and how might that influence pharmacy-led treatment planning?
Chavez: In this trial, there was no specific biomarker that predicted response or resistance to GOLCA. All high-risk subgroups responded similarly regardless of cell of origin or high-grade lymphoma status.
Pharmacy Times: Neutropenia and febrile neutropenia were among the most common AEs, especially at the 0.4 mg dose. What role do you envision for prophylactic G-CSF use or infection prevention protocols in real-world pharmacy practice?
Chavez: Using growth factors in DLBCL will be key while on GOLCA-R given the clinical trial experience. Some patients may require prophylactic antibiotics.
Pharmacy Times: With one treatment-related G5 event (ie, pneumonia), how should pharmacists approach risk assessment and patient education for immunosuppressive complications with GOLCA-R?
Chavez: Pharmacist will be key in providing counseling for infections, specifically related to neutropenia. Pharmacists should advocate for the use of growth factors, especially at earlier cycles when we see most of the cytopenias.
Patients who develop neutropenia may need prophylactic antibiotics. We did not see significant interaction between GOLCA and common antibiotics used for prevention.
Pharmacy Times: Since GOLCA 0.4 mg is moving forward to phase 3, what key factors supported that dose selection despite higher rates of neutropenia?
Chavez: In the early trials, we see a correlation between number of lines of therapy and incidence of cytopenia (ie, neutropenia), especially in patients that received autologous transplantation. Current trials with GOLCA are focusing on earlier lines (eg, frontline and second line), therefore I expect that cytopenia will be less frequent.
Pharmacy Times: What are the next steps in the phase 3 program for GOLCA-R, and how can pharmacists at clinical trial sites support its safe and effective implementation?
Chavez: The GOLSEEK-1 trial is the most important trial in DLBCL at this time (combination of GOLCA plus R-CHOP) which is ongoing. Adequate knowledge of the dosing and schedule will be key.
didi ng wing yin carves wood to evoke textile folds
Pleats Vase No.7 by Hong Kong–born, Helsinki-based artist Didi NG Wing Yin is among the finalists for the 2025 Loewe Craft Prize. Presented by Spazio Nobile and currently on view as part of The Nature of Wood group exhibition, the work combines woodcraft, sculpture, and functional design into a unified expression of surface and material honesty.
The vase is part of the artist’s larger Pleats Collection, which includes benches, chairs, a side table, a screen, and an umbrella holder. Each piece is hand-carved from solid timber, often ash or pine selected from local Finnish sources, and shaped into sculptural furniture pieces that evoke the softness of textile folds. Instead of manipulating the wood through steam or bending, the surface itself becomes the site of transformation. Didi creates the appearance of pleats by carving directly into the material, revealing the inner grain and reversing the wood’s usual outward form.
Didi NG Wing Yin, Pleats Vase No.7, Loewe Craft Prize 2025 | image courtesy Loewe Foundation
the pleats collection: a celebration of wood grain
With the Pleats Collection, artist Didi NG Wing Yin’s inspiration began with the simple observation of the irregular beauty of firewood’s split surface. Drawing from that origin, the works in the Pleats Collection expose the grain that is typically hidden, arranging it outward as a primary visual and tactile element. By brushing and inking the surface, using diluted Indian ink in layers, Didi deepens the contrast and movement within the pleated form.
Despite their apparent fragility, the vessels possess strength and integrity. Thin planks of wood are split, aligned by grain, joined seamlessly, and assembled into hollow forms. The inner walls are hand-carved to reduce weight and enhance translucency, creating a quiet interplay between density and air. What appears light and draped is in fact solid and precise, shaped through sustained physical engagement and acute spatial control.
Didi NG Wing Yin, Pleats Vase No.7, Loewe Craft Prize 2025 | image courtesy Loewe Foundation
traditional methods for contemporary sculpture
Didi NG Wing Yin’s subtractive and manual method of carving requires constant attentiveness to the wood’s resistance and flow. His tools are traditional, but the pleated forms feel contemporary, occupying at the edge of art and design. Rhythmic folds catch the light at varying angles, while brushed grain adds further layers of visual depth. Some surfaces are left nearly raw, while others are gently toned to draw attention to the grain’s curvature.
The result is a visual rhythm that feels alive, each vessel echoing a gesture in mid-motion. The design intelligence lies in the decision to trust the material and allow its subtleties to guide the process. For Didi, this is a meditative dialogue with the wood.
The artist’s background spans East Asian craft tradition and Nordic material sensibility, and his work brings these lineages into conversation. His process embraces ‘naturalness,’ a term he uses to describe the intuitive balance between control and surrender. This tension between hardness and softness is central to the Pleats Collection while each fold carries the trace of its making.
Travis Kelce reignites Taylor Swift engagement rumours as they approach their two-year anniversary
Travis Kelce knew just what he was doing when he posted that picture of Taylor Swift on his Instagram.
Over the weekend, the NFL star broke the internet as he finally went Instagram official with his pop superstar girlfriend. Taking a page straight out of Swift’s playbook, Kelce dropped multiple Easter Eggs throughout the photo dump featuring family, friends, and, of course, girlfriend. For instance, he posted exactly 13 photos, which is famously Swift’s lucky number.
But one detail that caught fans’ eyes was the photo that Kelce uses as his lockscreen; in the third slide, Kelce’s phone on the table clearly shows the power couple posing together as Taylor brings her hands up in front of her.
Fans wasted no time trying to zoom in on the picture to see if there was an engagement ring on Swift’s left hand.
“Looks like she’s holding up her hand to a… ring?” commented one fan under the post. Even Shark Tank star Barbara Corcoran joined in, commenting, “Me looking at Travis’ phone background.”
But though the picture itself was not enough to confirm it, wedding bells are definitely in Swift and Kelce’s future.
“They’re in a really solid place and more in sync than ever. They’re both all in,” a source told People magazine.
“Travis posting on his Instagram for the first time wasn’t random, it was intentional… this was his way of showing how serious things have become,” the insider continued.
“There’s no pressure between them, but they’re very aligned on where things are going,” they added.
Swift and Kelce, both 35, are approaching their two-year anniversary.
